A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia

Kotaro Oizumi, Takayosi Ohno, Masao Kawahara, Shinzo Kawaguchi, Masazumi Saisho, Yoshiyuki Mitutake, Akira Saito, Masumi Tomizawa, Takao Koike, Kazuo Takebe, Toyokazu Tamura, Hiroshi Inoue, Kazuki Konishi, Takashi Mohri, Sakura Katoh, Kenichi Takeuchi, Akiho Ohara, Haruhito Hirano, Hideki Ikeda, Kunio SiratoYasuo Tanno, Masato Tohno, Yasuo Ono, Takuya Suzuki, Masahiro Sakamoto, Akira Watanabe, Toshihiro Nukiwa, Kiyoshi Konno, Kuniharu Shida, Tsuneo Sayama, Kazuo Sato, Yoshiyuki Anzai, Yoshiki Anazawa, Susumu Yoshida, Akira Ohishi, Kohtaro Kaneko, Kaoru Shimada, Yasuyuki Sano, Norihisa Akiyama, Yasuo Arai, Mamoru Ohtomo, Koichiro Nakada, Tatsuo Nakatani, Naohiko Tyonabayashi, Koichiro Kudo, Hiroko Arioka, Harumi Shishido, Atsushi Takahashi, Atsuhisa Tamura, Hirofumi Katayama, Motoo Baba, Masaru Koyama, Kohji Murabayashi, Jingoro Shimada, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Takashi Oguri, Yoshihiro Hirai, Masaaki Arakawa, Shigeyuki Hoshino, Hiroki Tsukada, Nobuki Aoki, Saburo Izumi, Atsuhiko Sato, Tadakazu Hattori, Yutaka Nakano, Kenzo Takagi, Yasunobu Noda, Hideo Gonda, Toshihiko Takeuchi, Yasuo Yamada, Hidekazu Hanaki, Makoto Kawakami, Toshiyuki Yamamoto, Kanzo Suzuki, Toshinobu Yamamoto, Fumiyuki Kuze, Kenji Bando, Shinichiro Ohyama, Shohei Kusaka, Tadashi Ishida, Yoshiro Mochizuki, Rieko Kanan, Kazushige Tsuyuguchi, Kojiro Yasunaga, Seibun Yonezu, Yoshitaka Yamanaka, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Kazuya Higashino, Takashi Nakano, Tetsuya Nishigaki, Yumiko Goto, Hiroshi Sugimoto, Rinzo Soejima, Yoshihito Niki, Osamu Moriya, Akihisa Shindo, Toshiharu Matsushima, Makoto Kimura, Michio Yamakido, Kenji Hasegawa, Osamu Kurimura, Takehiko Hiramoto, Masahide Takii, Masanori Higuchi, Takaoki Ohyama, Katsuhiko Furuumi, Tsuneo Ishibashi, Masahiro Takamoto, Yasuko Harada, Susumu Harada, Kohei Hara, Hironobu Koga, Yoshiaki Ri, Taiji Masuyama, Masahiko Yoshimoto, Kazunori Shimoguchi, Kazuhiro Okuno, Kiyoyasu Fukushima, Keizo Matsumoto, Tsuyoshi Nagatake, Kazunori Oishi, Akihiro Hori, Tasuku Sakamoto, Hirofumi Tanaka, Toshihiro Morito, Mikio Fujishita, Masayuki Ando, Moritaka Suga, Naoki Saita, Masaru Nasu, Tohru Yamasaki, Jun Goto, Kazuo Kitagawa, Atsushi Saito, Hiroshi Fukuhara, Isoko Owan, Jun Inadome, Nobuya Ogawa, Koichi Deguchi

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    The efficacy, safety and usefulness of tazobactam/piperacillin (TAZ/PIPC), in bacterial pneumonia and lung abscess were determined with PIPC as the control in a multi-institutional comparative study a penicillin antibiotic for injection prepared by combining a newly developed β-lactamase inhibitor, tazobactam (TAZ), with a broad spectrum penicillin antibiotic, piperacillin (PIPC), at a ratio of 1:4. TAZ/PIPC was intravenously injected at a dose of 2.5 g (titer) twice a day, and PIPC at a dose of 2.0 g (titer) twice a day as a rule for 14 days. The following results were obtained: 1. The efficacy rates for bacterial pneumonia and lung abscess were 94% (80/85) in TAZ/PIPC group and 89% (70/79) in PIPC group, showing no significant difference between the two groups. 2. In a comparison of degrees of improvement in clinical symptoms, signs and laboratory findings, there were no significant differences between the two groups except for results on thoracic rales after three days of administration. 3. As for bacteriological effects, the elimination rates of causative organisms were 98% (40/41) in the TAZ/PIPC group and 80% (28/35) in the PIPC group. Thus, the TAZ/PIPC group was significantly superior to the PIPC group. The TAZ/PIPC group showed significantly better eradication of bacateria as well. Bacteria considered to be pyogenic were detected in 80 patients (43 administered TAZ/PIPC and 37 administered PIPC), but β-lactamase production was confirmed in only 11 patients of each group. There were no significant differences in bacteriological effects among these patients. Minimum inhibitory concentrations of TAZ/PIPC against β-lactamase producing organisms were distinctly superior to those of PIPC. 4. Side effects occurred in 10% (10/96) of the TAZ/PIPC group and 7% (7/95) of the PIPC group. Abnormal clinical laboratory test values were observed in 22% (20/92) of the TAZ/PIPC group and 18% (17/93) of the PIPC group. Thus, there were no significant differences between the two administration groups. 5. The usefulness rate in the TAZ/PIPC group was 87% (75/86) and it was 85% (67/79) in the PIPC group, showing no significant difference between them. The results suggest that TAZ/PIPC administered at a dose of 2.5 g (titer) twice a day is more useful than PIPC administered at a dose of 2.0 g (titer) twice a day in the treatment of bacterial pneumonia.

    Original languageEnglish
    Pages (from-to)449-481
    Number of pages33
    JournalThe Japanese Journal of Antibiotics
    Volume48
    Issue number4
    DOIs
    Publication statusPublished - 1995 Apr

    ASJC Scopus subject areas

    • Microbiology (medical)
    • Pharmacology (medical)
    • Infectious Diseases

    Fingerprint Dive into the research topics of 'A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia'. Together they form a unique fingerprint.

  • Cite this

    Oizumi, K., Ohno, T., Kawahara, M., Kawaguchi, S., Saisho, M., Mitutake, Y., Saito, A., Tomizawa, M., Koike, T., Takebe, K., Tamura, T., Inoue, H., Konishi, K., Mohri, T., Katoh, S., Takeuchi, K., Ohara, A., Hirano, H., Ikeda, H., ... Deguchi, K. (1995). A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia. The Japanese Journal of Antibiotics, 48(4), 449-481. https://doi.org/10.11553/antibiotics1968b.48.449